Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC2 | O75106 | 2/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 17/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30021100 | 0.91 | AOC2 (0.84) | AOC2AOC3KCNH2 | |
| SCHEMBL17610124 | 0.91 | AOC2 (0.84) | AOC2AOC3KCNH2 | |
| SCHEMBL17075546 | 0.78 | AOC3 (0.66) | AOC2AOC3KCNH2 | |
| SCHEMBL17075515 | 0.77 | AOC3 (0.71) | AOC2AOC3KCNH2 | |
| SCHEMBL18976981 | 0.77 | AOC3 (0.75) | AOC2AOC3KCNH2 | |
| SCHEMBL16048170 | 0.76 | AOC3 (0.70) | AOC2AOC3KCNH2 | |
| SCHEMBL18977381 | 0.76 | AOC3 (0.70) | AOC2AOC3KCNH2 | |
| SCHEMBL22997134 | 0.76 | AOC3 (0.77) | AOC2AOC3KCNH2 | |
| SCHEMBL17075549 | 0.75 | AOC3 (1.00) | AOC2AOC3KCNH2 | |
| SCHEMBL22620528 | 0.73 | AOC3 (0.68) | AOC2AOC3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PROXIMAGEN, LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-09-28 | — | — | US | disclosed |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PROXIMAGEN, LLC | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | AOC2 59/4885AOC3 55/4885KCNH2 1764/4885 |
| US-20170275281-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVED SSAO INHIBITORS | PNPO, SQOR, HAO1 | AOC2 10/4885AOC3 5/4885KCNH2 492/4885 |
| US-20200147059-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | VAPB, VAPA, SMOX | AOC2 5/4885AOC3 4/4885KCNH2 1505/4885 |
| US-11530208-B2 | Imidazo[4,5-C]pyridine derived SSAO inhibitors | PNPO, SQOR, HAO1 | AOC2 10/4885AOC3 5/4885KCNH2 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.